n-acetylputrescine profile

N-acetylputrescine is a derivative of the polyamine putrescine, formed by the acetylation of the primary amine group. It is synthesized in various organisms, including bacteria, plants, and animals. N-acetylputrescine plays a role in regulating cell growth and differentiation, and it is involved in various biological processes, such as spermidine biosynthesis, polyamine transport, and protection against oxidative stress. N-acetylputrescine has also been studied for its potential therapeutic effects in conditions like cancer and neurodegenerative diseases. Research focuses on understanding its role in polyamine metabolism, its contribution to cellular processes, and its potential as a target for drug development.'

N-acetylputrescine : An N-monoacetylalkane-alpha,omega-diamine that is the N-monoacetyl derivative of putrescine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	122356
CHEMBL ID	81241
CHEBI ID	17768
SCHEMBL ID	361286
MeSH ID	M0086335

Synonym
CHEMBL81241 ,
n-(4-aminobutyl)acetamide
CHEBI:17768 ,
n-acetylputrescine
5699-41-2
C02714
H12005
monoacetylputrescine
putrescine, n-acetyl-
36864054-D6F8-4927-901B-91A60738B493
A4036
n-acetylputrescinehydrochloride
AKOS005215796
n-acetyl-1,4-butanediamine
8ftm5zl5a6 ,
unii-8ftm5zl5a6
acetylputrescine
acetamide, n-(4-aminobutyl)-
bdbm50405938
4-acetylaminobutylamine
SCHEMBL361286
DTXSID80205596
mfcd10024834
NS-01048
Q27102595
n-(4-azanylbutyl)ethanamide
x5a ,
CS-0453679
Z600498842
n1-acetylputrescine
HY-W342604

Role	Description
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
mouse metabolite	Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
N-substituted putrescine
N-monoacetylalkane-alpha,omega-diamine	An acetamide obtained by acetylation of one of the amino groups of any alkane-alpha,omega-diamine. AcNHCH2(CH2)nCH2NH2, where n = 0, 1, 2, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Arginine and Proline metabolism ( Arginine and Proline metabolism )	42	55
GABA metabolism (aka GHB)	11	28

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)	Ki	800.0000	0.1000	0.2767	0.5500	AID144352
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
putrescine biosynthetic process	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
putrescine catabolic process	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
spermidine catabolic process	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
spermine catabolic process	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
positive regulation of spermidine biosynthetic process	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
polyamine oxidase activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
N(1),N(12)-diacetylspermine:oxygen oxidoreductase (3-acetamidopropanal-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
spermine:oxygen oxidoreductase (spermidine-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
spermidine:oxygen oxidoreductase (3-aminopropanal-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
N1-acetylspermine:oxygen oxidoreductase (3-acetamidopropanal-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
N1-acetylspermidine:oxygen oxidoreductase (3-acetamidopropanal-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
peroxisomal matrix	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
cytosol	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID144352	Ability to inhibit the deacetylation of [acetyl-3H]-N8-Acetylspermidine deacetylase in rat liver.	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Design and synthesis of inhibitors of N8-acetylspermidine deacetylase.
AID144355	In vitro inhibition of N8-Acetylspermidine deacetylase from rat liver cytosol(apparent Ki)	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	Inhibition of N8-acetylspermidine deacetylase by active-site-directed metal coordinating inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15 (44.12)	18.7374
1990's	11 (32.35)	18.2507
2000's	1 (2.94)	29.6817
2010's	3 (8.82)	24.3611
2020's	4 (11.76)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.78%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	35 (97.22%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.38	2	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
5-aminovaleric acid 5-aminovaleric acid: from red fox anal secretion; RN given refers to parent cpd. 5-aminopentanoic acid : A delta-amino acid comprising pentanoic acid with an amino substituent at C-5; a methylene homologue of gamma-aminobutyric acid (GABA) that is a weak GABA agonist.	1.98	1	amino acid zwitterion; delta-amino acid; omega-amino fatty acid	human metabolite
butyric acid Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.	2.25	1	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
cadaverine [no description available]	2.4	2	alkane-alpha,omega-diamine	Daphnia magna metabolite; Escherichia coli metabolite; mouse metabolite; plant metabolite
carnitine [no description available]	2.25	1	amino-acid betaine	human metabolite; mouse metabolite
chlordecone [no description available]	1.97	1	cyclic ketone; organochlorine compound	insecticide; persistent organic pollutant
trimethylenediamine trimethylenediamine: RN given refers to parent cpd; structure. trimethylenediamine : An alkane-alpha,omega-diamine comprising a propane skeleton with amino substituents at positions 1 and 3.	1.98	1	alkane-alpha,omega-diamine	human metabolite; mouse metabolite; reagent
n(1)-acetylspermidine N(1)-acetylspermidine : An acetylspermidine having the acetyl group at the N1-position.	5.08	14	acetylspermidine	Escherichia coli metabolite; metabolite
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	1.98	1	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
glycine [no description available]	2.13	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
histamine [no description available]	1.99	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
n'-acetylspermine N(1)-acetylspermine : An acetylspermine carrying an acetyl group at position N(1).	2.66	3	acetamides; acetylspermine	human metabolite
putrescine [no description available]	5.89	32	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
spermidine [no description available]	10.32	18	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine [no description available]	3.06	5	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
1,10-phenanthroline 1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases	1.98	1	phenanthroline	EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
2,2'-dipyridyl 2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.	1.98	1	bipyridine	chelator; ferroptosis inhibitor
n-acetyltryptophan N-acetyltryptophan : An N-acetylamino acid that is the N-acetyl derivative of tryptophan.	2.25	1	N-acetyl-amino acid; tryptophan derivative	metabolite
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	2.31	1	alpha-amino acid; fluoroamino acid	trypanocidal drug
hexamethylene bisacetamide N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208	2.37	2	acetamides
iodoacetamide [no description available]	1.98	1
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	1.98	1	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
carbamylhydrazine carbamylhydrazine: RN given refers to parent cpd	1.99	1	carbohydrazide; monocarboxylic acid amide; one-carbon compound; ureas
isoflurophate Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.	1.98	1	dialkyl phosphate
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	1.98	1	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.25	1	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
chloroform Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.	1.97	1	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	2.25	1	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
bromotrichloromethane Bromotrichloromethane: A potent liver poison. In rats, bromotrichloromethane produces about three times the degree of liver microsomal lipid peroxidation as does carbon tetrachloride.	1.97	1
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	1.98	1	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
benzylamine aminotoluene : Any member of the class of toluenes carrying one or more amino groups.	1.99	1	aralkylamine; primary amine	allergen; EC 3.5.5.1 (nitrilase) inhibitor; plant metabolite
ethyl chloroformate [no description available]	1.96	1
dansyl chloride dansyl chloride: RN given refers to unlabeled cpd	1.96	1	aminonaphthalene; sulfonic acid derivative
salvin salvin: a biocyclic diterpenoid; from sage and rosemary (Lamiaceae)	2.1	1	abietane diterpenoid; carbotricyclic compound; catechols; monocarboxylic acid	angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; food preservative; HIV protease inhibitor; plant metabolite
4,7-phenanthroline [no description available]	1.98	1	phenanthroline
coronatine coronatine: consists of a coronafacic acid joined by an amide bond to coronamic acid by coronafacate ligase; phytotoxin produced by Pseudomonas syringae; RN given refers to (3aS-(3aalpha,4(1R,2R),6beta,7alpha))-isomer;	2.13	1	N-acyl-amino acid
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.4	2
caprylates Caprylates: Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.. octanoate : A straight-chain saturated fatty acid anion that is the conjugate base of octanoic acid (caprylic acid); believed to block adipogenesis.	2.25	1	fatty acid anion 8:0; straight-chain saturated fatty acid anion	human metabolite; Saccharomyces cerevisiae metabolite
n(8)-acetylspermidine N(8)-acetylspermidine : An acetylspermidine that is 1,8-diamino-4-azaoctane in which one of the hydrogens of the amino group attached to C-8 is replaced by an acetyl group.	3.58	9	acetylspermidine	Escherichia coli metabolite; human metabolite
7-(n-(3-aminopropyl)amino)heptan-2-one 7-(N-(3-aminopropyl)amino)heptan-2-one: inhibits N(8)-acetylspermidine deacetylation in mice	1.97	1
n-acetyl-1,6-diaminohexane [no description available]	1.97	1
monoacetylcadaverine monoacetylcadaverine: found in higher levels in blood of schizophrenic patients; substrate for rat liver monoamine oxidase & hog kidney diamine oxidase; RN from Vol 90, CA Chem Form Index. N-acetylcadaverine : An N-substituted cadaverine that is cadaverine in which one of the amino groups has been converted to the corresponding acetamide.	1.96	1	acetamides; N-substituted cadaverine; primary amino compound; secondary carboxamide	human metabolite
carnosol carnosol: isolated from Lepechinia hastata	2.1	1	diterpenoid
sodium butyrate [no description available]	1.98	1	organic sodium salt	EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
methionine sulfoxide methionine sulfoxide: RN given refers to cpd without isomeric designation. L-methionine (R)-S-oxide : The (R)-oxido diastereomer of L-methionine S-oxide.	2.25	1	amino acid zwitterion; L-methionine S-oxide	Escherichia coli metabolite
3,5-diethoxy-4-aminomethylpyridine 3,5-diethoxy-4-aminomethylpyridine: reversible inhibitor of benzylamine oxidase	1.99	1
putreanine [no description available]	1.97	1	carboxylic acid anion; N-substituted putrescine; organonitrogen compound; organooxygen compound

Condition	Relationship Strength	Studies
Rheumatoid Arthritis [description not available]	2.25	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.25	1
Orphan Diseases Rare diseases that have not been well studied.	2.31	1
Alopecia Cicatrisata [description not available]	2.31	1
Alopecia Absence of hair from areas where it is normally present.	2.31	1
Breast Cancer [description not available]	2.05	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.05	1
Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.	2.05	1
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	1.96	1
Benign Neoplasms, Brain [description not available]	2.88	1
Leukemia, Lymphocytic [description not available]	3.28	2
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	2.88	1
Benign Neoplasms [description not available]	3.28	2
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.88	1
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	3.28	2
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	2.88	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.28	2
Acute Myelogenous Leukemia [description not available]	1.96	1
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	1.96	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1.96	1
Cancer of Ovary [description not available]	1.96	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1.96	1
Leucocythaemia [description not available]	1.96	1
Malignant Melanoma [description not available]	1.96	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	1.96	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.96	1
Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)	1.96	1
Experimental Hepatoma [description not available]	1.96	1
Cardiomyopathies, Primary [description not available]	1.99	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.99	1
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	1.99	1
Acute Liver Injury, Drug-Induced [description not available]	1.97	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	1.97	1

n-acetylputrescine

Description

Cross-References

Synonyms (31)

Roles (2)

Drug Classes (2)

Pathways (2)

Protein Targets (1)

Inhibition Measurements

Biological Processes (5)

Molecular Functions (6)

Ceullar Components (2)

Bioassays (2)

Research

Studies (34)

Market Indicators

Research Demand Index: 34.21

Study Types